Article
New progress in treatment of hormone-refractory prostate cancer
Lancet Oncology
Publication Date
12-1-2004
Document Type
Article
Disciplines
Abstract
Two studies have shown that docetaxel-based regimens yield better survival, pain control, and quality of life for patients with advanced hormone-refractory prostate cancer than do mitoxantrone-based regimens.
Citation Information
Khabir Ahmed. "New progress in treatment of hormone-refractory prostate cancer" Lancet Oncology Vol. 5 Iss. 12 (2004) p. 706 Available at: http://works.bepress.com/khabir_ahmed/50/